Sylentis reports positive Phase II results with SYL1001 in treating ocular pain
Sylentis, a pharmaceutical company in the PharmaMar Group (MSE:PHM) and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has presented the...